The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1275 articles
Peptides, once a Silicon Valley biohacking secret, are exploding in popularity—search interest now tops Ozempic. With RFK Jr. poised to reverse FDA restrictions, compounding pharmacies and telehealth platforms are racing to supply them legally. This could propel the $52B peptide market to $87B by 2035.
In a strategic move, Novo Nordisk has elected Poul Weihrauch, CEO of Mars, as a board observer to enhance its consumer presence in the competitive US obesity market. This comes alongside new board members and a 2025 leadership overhaul. The appointment underscores efforts to make Wegovy more accessible through telehealth and direct-to-consumer channels.
Hims & Hers Health, Inc. has partnered with Novo Nordisk to bring a broad assortment of FDA-approved GLP-1 medications to eligible customers, including the groundbreaking Wegovy® pill. This collaboration simplifies access with affordable prices, expanded doses, and diverse delivery methods. As the largest global consumer health platform for these approved meds, Hims & Hers is transforming weight management options.
Researchers have pinpointed that GLP-1 receptors (GLP-1R) in kidney vascular smooth muscle cells play a crucial role in blood pressure regulation. In mouse studies, semaglutide lowered BP only when these receptors were intact, highlighting a novel pathway independent of weight loss. This could reshape our understanding of GLP-1 therapies in hypertension.
Ozempic, the blockbuster semaglutide drug from Novo Nordisk, is set to go generic in India as early as this weekend, with China, Brazil, Turkey, and South Africa following. This could drop prices to $15 per month, opening access to millions with obesity and diabetes. Meanwhile, U.S. and Europe face delays until 2030 due to patent extensions.
Reality star Layla Taylor shares her concerning experience obtaining a GLP-1 prescription with alarming ease in Utah, revealing how the medication became an 'unhealthy crutch' amid her long-term battle with an eating disorder. Her story highlights critical gaps in patient screening and mental health considerations.
As generic GLP-1 drugs flood the Indian market post-patent expiry, Dr. Naresh Trehan warns they shouldn't be available over-the-counter due to serious side effects. Government advisories stress medical supervision to prevent misuse. Experts like Dr. Gupta and Dr. Bhattacharya highlight risks of self-medication with semaglutide and liraglutide.
Severe ankle pain led Jelon Smart to Ozempic, where she dropped 30 pounds quickly—but plateaued until adding exercise. Doctors like Dafina Allen and Gerald Onuoha stress that GLP-1s alone aren't enough; movement, mental health, and monitored dosing are key for long-term success and safety.
A groundbreaking phase 3 trial shows orforglipron, a new daily oral weight-loss pill, surpassing oral semaglutide in blood sugar control and weight reduction for type 2 diabetes patients. This small-molecule GLP-1 agonist offers advantages over injectables like Ozempic by eliminating needles and refrigeration needs. However, higher gastrointestinal side effects raise questions about long-term tolerability.
